News & Events
- Jul 21, 2010 BV 4 Portfolio Company Alnara Pharmaceuticals: Lilly Announces Completion of Acquisition | Download PDF version
- Jul 08, 2010 BV 4 Portfolio Company iPierian Closes $22 Million Series B Financing Led By Google Ventures | Download PDF version
- Jul 06, 2010 BV 2 Portfolio Company SenoRx Completes Sale to C. R. Bard | Download PDF version
- Jul 02, 2010 BV 4 Portfolio Company Alnara Pharmaceuticals to be Acquired by Lilly | Download PDF version
- Jun 28, 2010 BV 4 Portfolio Company Chiasma Receives Orphan Drug Designation From The FDA | Download PDF version
- Jun 28, 2010 BV 2 Portfolio Company Gilead Sciences to Acquire CGI Pharmaceuticals for Up to $120 Million | Download PDF version
- Jun 21, 2010 BV 5 Portfolio Company Rhythm announces RM-493 Reverses Obesity and Insulin Resistance in Obese Primates
- Jun 14, 2010 BV 4 Portfolio Company Chiasma announces successful oral delivery of a peptide in a clinical trial and plans to initiate a pivotal trial by year end | Download PDF version
- May 20, 2010 BV 5 Portfolio Company Neurotherapeutics Pharma Closes $43 Million Series B Financing and Adds Four New Investors | Download PDF version
- May 05, 2010 BV 2 Portfolio Company SenoRx to be Acquired by C. R. Bard for Approximately $213 Million | Download PDF version
- Apr 30, 2010 BV 4 Portfolio Company iPierian Awarded Basic Biology Grant by California Institute of Regenerative Medicine to Study Cellular
- Apr 01, 2010 BV 3 & BV 4 Portfolio Company Xanodyne and Ferring Announce Co-Promote for Zipsor
- Mar 29, 2010 BV 4 Portfolio Company Epizyme Expands Leadership Team, Appointing Robert Gould, Ph.D. as CEO and Jason Rhodes as EVP and CBO
- Mar 15, 2010 BV 3 Portfolio Company Portola Pharmaceuticals and Merck Announce Results of Phase 2 Study of Betrixaban
- Mar 15, 2010 BV 5 Portfolio Company Rhythm Announces $21 Million Series A | Download PDF version
- Mar 02, 2010 BV 3 Portfolio Company CombinatoRx Achieves $40 Million Milestone | Download PDF version
- Feb 25, 2010 BV 4 Portfolio Company Alnara Pharmaceuticals Expands Leadership Team and Scientific Advisory Board (pdf) | Download PDF version
- Jan 29, 2010 First iPierian (a BV4 Portfolio Company) Patent for Induced Pluripotent Stem Cell Technology Granted by the United Kingdom Intellectual Property Office | Download PDF version
- Jan 28, 2010 MPM BV4 leads $35mm Series B financing for Alnara Pharmaceuticals
- Jan 26, 2010 Paper entitled “Protein Methyltransferases as Target Class for Drug Discovery” by BV4 Portfolio Company Epizyme Scientists published in Nature Reviews Drug Discovery
- Jan 22, 2010 BV3 Portfolio Company Somaxon Provides Update On New Drug Application For SILENOR® For The Treatment Of Insomnia
- Jan 20, 2010 Gambro announces agreement to acquire CHF Solutions, Inc., a BV1 & BV3 Portfolio Company
- Jan 19, 2010 BV4 Portfolio Company Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products | Download PDF version
- Jan 06, 2010 BV3 Portfolio Company CombinatorRx Announces Senior Management Team Changes
- Dec 22, 2009 BV3 Portfolio Company Neuromed and CombinatoRx Close Merger
- Dec 22, 2009 BV4 Portfolio Company iPierian Highlighted In December 17, 2009 New York Times Article
- Dec 04, 2009 Proteon Therapeutics Named 2010 Technology Pioneer by the World Economic Forum | Download PDF version
- Dec 02, 2009 BV4 Portfolio Company Pacira Pharmaceuticals Announces Results of Another Positive Phase III Trial in Post Operative Pain
- Nov 20, 2009 BV4 Portfolio Company TriVascular, Inc. Secures $30 Million in Equity Financing
- Nov 20, 2009 BV2 Portfolio Company EKR Therapeutics Named Private Company of the Year By New Jersey Technology Council
- Nov 20, 2009 ABC News Segment on BV4 Portfolio Company iPierian
- Nov 12, 2009 BV4 Portfolio Company Peplin Acquired By LEO Pharma | Download PDF version
- Nov 09, 2009 BV4 Portfolio Company NeoVista, Inc. Announces Initial VIDION® Shipments | Download PDF version
- Nov 06, 2009 BV4 Portfolio Company NeoVista®, Inc. Completes Enrollment in Pivotal CABERNET™ Study
- Nov 05, 2009 BV2 Portfolio Company Biovitrum AB to Purchase Drug Company Swedish Orphan | Download PDF version
- Nov 03, 2009 BV4 Portfolio Company EKR Therapeutics Receives Notice of Patent Allowance for Ready-to-Use Cardene® I.V. Bags
- Nov 03, 2009 BV4 Portfolio Company Epizyme Appoints Hoyoung Huh, MD, Ph.D., Chairman of the Board of Directors
- Oct 21, 2009 BV4 Portfolio Company iPierian To Collaborate with Johns Hopkins University on $3.7 Million NIH Grand Opportunities Grant
- Oct 08, 2009 BV4 Portfolio Company Epizyme Closes $32 Million Series B Financing
- Sep 17, 2009 BV4 Portfolio Company iPierian Featured In Forbes Magazine Article, October 5, 2009 Issue: "Growing Diseases In A Dish”
- Sep 10, 2009 BV3 Portfolio Company Quatrx Announces Positive Results Of Second Pivotal Phase 3 Clinical Study | Download PDF version
- Sep 07, 2009 BV2 Portfolio Company PrimeraDx closes $20m Series C
- Sep 03, 2009 LEO Pharma to Acquire BV3 & BV4 Portfolio Company Peplin for US$287.5m | Download PDF version
- Aug 24, 2009 BV2 & BV3 Portfolio Company EGS Announces Initiation of Clinical Study to Demonstrate Efficacy of StomaphyX for Revisional Weight Loss Surgery
- Jul 09, 2009 Merck & Co., Inc. and BV3 Portfolio Company Portola Enter Worldwide License Agreement to Develop and Commercialize Betrixaban, | Download PDF version
- Jul 08, 2009 iZumi Bio and Pierian Merge to form BV4 Portfolio Company iPierian to Advance Cellular Reprogramming | Download PDF version
- Jul 08, 2009 CEO of BV2 Portfolio Company AVEO Pharmaceuticals discusses testing strategies
- Jul 07, 2009 BV3 Portfolio Company Somaxon Pharma PIPEs $6 Million
- Jul 02, 2009 Four MPM companies listed in the “Fierce 15” for 2009
- Jul 02, 2009 BV3 Portfolio Company Neuromed and CombinatoRx Sign Merger Agreement | Download PDF version
- Jun 25, 2009 Howard Weisman, Chairman & CEO of BV4 Portfolio Company EKR Therapeutics, Named Ernst & Young Entrepreneur Of The Year® 2009 Award Winner For The New Jersey Pharmaceutical Industry | Download PDF version
- Jun 17, 2009 BV3 & BV4 Portfolio Company Xanodyne Receives Approval From the U.S. Food and Drug Administration for ZIPSOR™ (diclofenac potassium) Liquid Filled Capsules
- Jun 17, 2009 BV3 Portfolio Company Neuromed Announces Sale of U.S. Rights to Drug Candidate to Exgalgo™ to Mallinckrodt | Download PDF version
- Jun 11, 2009 Proteon Founders Named Entrepreneurs Of The Year® 2009 Award Winners in the Central Midwest Region | Download PDF version
- Jun 05, 2009 BV3 & BV4 Portfolio Company Xanodyne Announces New President/CEO and Completes $38 million equity financing | Download PDF version
- Jun 01, 2009 BV1 & BV4 Portfolio Company Valeritas Announces Appointment of New CEO
- May 29, 2009 Proteon Therapeutics Completes Second Closing of Equity Financing | Download PDF version
- May 26, 2009 BV2 Portfolio Company Elixir Pharmaceuticals Signs Option Agreement with a Major Pharmaceutical Company | Download PDF version
- Mar 31, 2009 BV3 Portfolio Company Quatrx Completes Enrollment of Ophena™ - Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy | Download PDF version
- Mar 30, 2009 BV2 & BV3 Portfolio Company EGS Announces Publication of Cadiere's TIF Study 2-Year Results | Download PDF version
- Mar 23, 2009 BV3 Portfolio Company Neuromed Announces Exalgo Extended-Release Tablets Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial | Download PDF version
- Mar 19, 2009 BV4 Portfolio Company NeoVista, Inc. Closes $18 million Series “D” Preferred Venture Financing Round | Download PDF version
- Mar 12, 2009 European Commission Approves ReFacto AF(TM) as a Variation to the Refacto(R) Marketing Authorisation | Download PDF version
- Mar 09, 2009 BV4 Portfolio Company Surface Logix Raises $20 Million in Financing | Download PDF version
- Mar 09, 2009 BV4 Portfolio Company Solasia - First Drug Trial Initiated in Japan (pdf) | Download PDF version
- Mar 05, 2009 Proteon Therapeutics Completes $38M Equity Financing | Download PDF version
- Feb 23, 2009 Novartis and BV3 Portfolio Company Portola ink potential $575M deal | Download PDF version
- Jan 16, 2009 BV3 Portfolio Company Peptimmune grants Novartis exclusive option to license PI-2301 for multiple sclerosis | Download PDF version
- Jun 11, 2008 Ipsen to Acquire BV3 Portfolio Company Tercica | Download PDF version
- May 13, 2008 MPM Invests in India CRO BV4 Portfolio Company SAI ADVANTIUM | Download PDF version
- Apr 15, 2008 BV4 Portfolio Company Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam® | Download PDF version
- Mar 31, 2008 MPM Capital and NEA Finance BV4 Portfolio Company TriVascular2 | Download PDF version
- Mar 24, 2008 Robert Millman and Dr. Elizabeth Stoner join MPM Senior Investment Team | Download PDF version
- Mar 10, 2008 BV4 Portfolio Company EKR Raises over $145 million | Download PDF version
- Dec 12, 2007 BV3 & BV4 Portfolio Company Peplin reports Phase IIa AK data | Download PDF version
- Nov 12, 2007 BV4 Portfolio Company NeoVista data on Wet AMD presented at AAO | Download PDF version
- Oct 01, 2007 Perkin Elmer to Acquire BV1 & BV2 Portfolio Company ViaCell | Download PDF version
- Aug 03, 2007 BV3 Portfolio Company Pharmathene and HAQ Merger Completed | Download PDF version
- Jun 22, 2007 SkyePharma Inc. Announces Name Change to BV4 Portfolio Company Pacira Pharmaceuticals | Download PDF version
- Jun 11, 2007 New York TImes: GP Luke Evnin on Medical Device Investing | Download PDF version
- Apr 26, 2007 MPM Capital and Reliance Life Sciences Partner to Build Biotechnology in India | Download PDF version